Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the relaxin in acute heart failure (RELAX-AHF) development program

Correlation with outcomes

Marco Metra, Gad Cotter, Beth A. Davison, G. Michael Felker, Gerasimos Filippatos, Barry H. Greenberg, Piotr Ponikowski, Elaine Unemori, Adriaan A. Voors, Kirkwood F. Adams, Maria I. Dorobantu, Liliana Grinfeld, Guillaume Jondeau, Alon Marmor, Josep Masip, Peter Pang, Karl Werdan, Margaret F. Prescott, Christopher Edwards, Sam L. Teichman & 6 others Angelo Trapani, Christopher A. Bush, Rajnish Saini, Christoph Schumacher, Thomas Severin, John R. Teerlink

Research output: Contribution to journalArticle

291 Citations (Scopus)

Abstract

Objectives: The aim of this study was to assess the effects of serelaxin on short-term changes in markers of organ damage and congestion and relate them to 180-day mortality in patients with acute heart failure. Background: Hospitalization for acute heart failure is associated with high post-discharge mortality, and this may be related to organ damage. Methods: The Pre-RELAX-AHF (Relaxin in Acute Heart Failure) phase II study and RELAX-AHF phase III study were international, multicenter, double-blind, placebo-controlled trials in which patients hospitalized for acute heart failure were randomized within 16 h to intravenous placebo or serelaxin. Each patient was followed daily to day 5 or discharge and at days 5, 14, and 60 after enrollment. Vital status was assessed through 180 days. In RELAX-AHF, laboratory evaluations were performed daily to day 5 and at day 14. Plasma levels of biomarkers were measured at baseline and days 2, 5, and 14. All-cause mortality was assessed as a safety endpoint in both studies. Results: Serelaxin reduced 180-day mortality, with similar effects in the phase II and phase III studies (combined studies: N = 1,395; hazard ratio: 0.62; 95% confidence interval: 0.43 to 0.88; p = 0.0076). In RELAX-AHF, changes in markers of cardiac (high-sensitivity cardiac troponin T), renal (creatinine and cystatin-C), and hepatic (aspartate transaminase and alanine transaminase) damage and of decongestion (N-terminal pro-brain natriuretic peptide) at day 2 and worsening heart failure during admission were associated with 180-day mortality. Serelaxin administration improved these markers, consistent with the prevention of organ damage and faster decongestion. Conclusions: Early administration of serelaxin was associated with a reduction of 180-day mortality, and this occurred with fewer signs of organ damage and more rapid relief of congestion during the first days after admission.

Original languageEnglish (US)
Pages (from-to)196-206
Number of pages11
JournalJournal of the American College of Cardiology
Volume61
Issue number2
DOIs
StatePublished - Jan 15 2013
Externally publishedYes

Fingerprint

Relaxin
Heart Failure
Biomarkers
Kidney
Liver
Mortality
Placebos
Cystatin C
Troponin T
Brain Natriuretic Peptide
Aspartate Aminotransferases
Alanine Transaminase
Creatinine
Hospitalization
Confidence Intervals
Safety

Keywords

  • congestion
  • heart failure
  • organ protection
  • RELAX-AHF
  • serelaxin

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the relaxin in acute heart failure (RELAX-AHF) development program : Correlation with outcomes. / Metra, Marco; Cotter, Gad; Davison, Beth A.; Felker, G. Michael; Filippatos, Gerasimos; Greenberg, Barry H.; Ponikowski, Piotr; Unemori, Elaine; Voors, Adriaan A.; Adams, Kirkwood F.; Dorobantu, Maria I.; Grinfeld, Liliana; Jondeau, Guillaume; Marmor, Alon; Masip, Josep; Pang, Peter; Werdan, Karl; Prescott, Margaret F.; Edwards, Christopher; Teichman, Sam L.; Trapani, Angelo; Bush, Christopher A.; Saini, Rajnish; Schumacher, Christoph; Severin, Thomas; Teerlink, John R.

In: Journal of the American College of Cardiology, Vol. 61, No. 2, 15.01.2013, p. 196-206.

Research output: Contribution to journalArticle

Metra, M, Cotter, G, Davison, BA, Felker, GM, Filippatos, G, Greenberg, BH, Ponikowski, P, Unemori, E, Voors, AA, Adams, KF, Dorobantu, MI, Grinfeld, L, Jondeau, G, Marmor, A, Masip, J, Pang, P, Werdan, K, Prescott, MF, Edwards, C, Teichman, SL, Trapani, A, Bush, CA, Saini, R, Schumacher, C, Severin, T & Teerlink, JR 2013, 'Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the relaxin in acute heart failure (RELAX-AHF) development program: Correlation with outcomes', Journal of the American College of Cardiology, vol. 61, no. 2, pp. 196-206. https://doi.org/10.1016/j.jacc.2012.11.005
Metra, Marco ; Cotter, Gad ; Davison, Beth A. ; Felker, G. Michael ; Filippatos, Gerasimos ; Greenberg, Barry H. ; Ponikowski, Piotr ; Unemori, Elaine ; Voors, Adriaan A. ; Adams, Kirkwood F. ; Dorobantu, Maria I. ; Grinfeld, Liliana ; Jondeau, Guillaume ; Marmor, Alon ; Masip, Josep ; Pang, Peter ; Werdan, Karl ; Prescott, Margaret F. ; Edwards, Christopher ; Teichman, Sam L. ; Trapani, Angelo ; Bush, Christopher A. ; Saini, Rajnish ; Schumacher, Christoph ; Severin, Thomas ; Teerlink, John R. / Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the relaxin in acute heart failure (RELAX-AHF) development program : Correlation with outcomes. In: Journal of the American College of Cardiology. 2013 ; Vol. 61, No. 2. pp. 196-206.
@article{346b0f0ac917495c9ebb6cfaf80f53d6,
title = "Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the relaxin in acute heart failure (RELAX-AHF) development program: Correlation with outcomes",
abstract = "Objectives: The aim of this study was to assess the effects of serelaxin on short-term changes in markers of organ damage and congestion and relate them to 180-day mortality in patients with acute heart failure. Background: Hospitalization for acute heart failure is associated with high post-discharge mortality, and this may be related to organ damage. Methods: The Pre-RELAX-AHF (Relaxin in Acute Heart Failure) phase II study and RELAX-AHF phase III study were international, multicenter, double-blind, placebo-controlled trials in which patients hospitalized for acute heart failure were randomized within 16 h to intravenous placebo or serelaxin. Each patient was followed daily to day 5 or discharge and at days 5, 14, and 60 after enrollment. Vital status was assessed through 180 days. In RELAX-AHF, laboratory evaluations were performed daily to day 5 and at day 14. Plasma levels of biomarkers were measured at baseline and days 2, 5, and 14. All-cause mortality was assessed as a safety endpoint in both studies. Results: Serelaxin reduced 180-day mortality, with similar effects in the phase II and phase III studies (combined studies: N = 1,395; hazard ratio: 0.62; 95{\%} confidence interval: 0.43 to 0.88; p = 0.0076). In RELAX-AHF, changes in markers of cardiac (high-sensitivity cardiac troponin T), renal (creatinine and cystatin-C), and hepatic (aspartate transaminase and alanine transaminase) damage and of decongestion (N-terminal pro-brain natriuretic peptide) at day 2 and worsening heart failure during admission were associated with 180-day mortality. Serelaxin administration improved these markers, consistent with the prevention of organ damage and faster decongestion. Conclusions: Early administration of serelaxin was associated with a reduction of 180-day mortality, and this occurred with fewer signs of organ damage and more rapid relief of congestion during the first days after admission.",
keywords = "congestion, heart failure, organ protection, RELAX-AHF, serelaxin",
author = "Marco Metra and Gad Cotter and Davison, {Beth A.} and Felker, {G. Michael} and Gerasimos Filippatos and Greenberg, {Barry H.} and Piotr Ponikowski and Elaine Unemori and Voors, {Adriaan A.} and Adams, {Kirkwood F.} and Dorobantu, {Maria I.} and Liliana Grinfeld and Guillaume Jondeau and Alon Marmor and Josep Masip and Peter Pang and Karl Werdan and Prescott, {Margaret F.} and Christopher Edwards and Teichman, {Sam L.} and Angelo Trapani and Bush, {Christopher A.} and Rajnish Saini and Christoph Schumacher and Thomas Severin and Teerlink, {John R.}",
year = "2013",
month = "1",
day = "15",
doi = "10.1016/j.jacc.2012.11.005",
language = "English (US)",
volume = "61",
pages = "196--206",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier USA",
number = "2",

}

TY - JOUR

T1 - Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the relaxin in acute heart failure (RELAX-AHF) development program

T2 - Correlation with outcomes

AU - Metra, Marco

AU - Cotter, Gad

AU - Davison, Beth A.

AU - Felker, G. Michael

AU - Filippatos, Gerasimos

AU - Greenberg, Barry H.

AU - Ponikowski, Piotr

AU - Unemori, Elaine

AU - Voors, Adriaan A.

AU - Adams, Kirkwood F.

AU - Dorobantu, Maria I.

AU - Grinfeld, Liliana

AU - Jondeau, Guillaume

AU - Marmor, Alon

AU - Masip, Josep

AU - Pang, Peter

AU - Werdan, Karl

AU - Prescott, Margaret F.

AU - Edwards, Christopher

AU - Teichman, Sam L.

AU - Trapani, Angelo

AU - Bush, Christopher A.

AU - Saini, Rajnish

AU - Schumacher, Christoph

AU - Severin, Thomas

AU - Teerlink, John R.

PY - 2013/1/15

Y1 - 2013/1/15

N2 - Objectives: The aim of this study was to assess the effects of serelaxin on short-term changes in markers of organ damage and congestion and relate them to 180-day mortality in patients with acute heart failure. Background: Hospitalization for acute heart failure is associated with high post-discharge mortality, and this may be related to organ damage. Methods: The Pre-RELAX-AHF (Relaxin in Acute Heart Failure) phase II study and RELAX-AHF phase III study were international, multicenter, double-blind, placebo-controlled trials in which patients hospitalized for acute heart failure were randomized within 16 h to intravenous placebo or serelaxin. Each patient was followed daily to day 5 or discharge and at days 5, 14, and 60 after enrollment. Vital status was assessed through 180 days. In RELAX-AHF, laboratory evaluations were performed daily to day 5 and at day 14. Plasma levels of biomarkers were measured at baseline and days 2, 5, and 14. All-cause mortality was assessed as a safety endpoint in both studies. Results: Serelaxin reduced 180-day mortality, with similar effects in the phase II and phase III studies (combined studies: N = 1,395; hazard ratio: 0.62; 95% confidence interval: 0.43 to 0.88; p = 0.0076). In RELAX-AHF, changes in markers of cardiac (high-sensitivity cardiac troponin T), renal (creatinine and cystatin-C), and hepatic (aspartate transaminase and alanine transaminase) damage and of decongestion (N-terminal pro-brain natriuretic peptide) at day 2 and worsening heart failure during admission were associated with 180-day mortality. Serelaxin administration improved these markers, consistent with the prevention of organ damage and faster decongestion. Conclusions: Early administration of serelaxin was associated with a reduction of 180-day mortality, and this occurred with fewer signs of organ damage and more rapid relief of congestion during the first days after admission.

AB - Objectives: The aim of this study was to assess the effects of serelaxin on short-term changes in markers of organ damage and congestion and relate them to 180-day mortality in patients with acute heart failure. Background: Hospitalization for acute heart failure is associated with high post-discharge mortality, and this may be related to organ damage. Methods: The Pre-RELAX-AHF (Relaxin in Acute Heart Failure) phase II study and RELAX-AHF phase III study were international, multicenter, double-blind, placebo-controlled trials in which patients hospitalized for acute heart failure were randomized within 16 h to intravenous placebo or serelaxin. Each patient was followed daily to day 5 or discharge and at days 5, 14, and 60 after enrollment. Vital status was assessed through 180 days. In RELAX-AHF, laboratory evaluations were performed daily to day 5 and at day 14. Plasma levels of biomarkers were measured at baseline and days 2, 5, and 14. All-cause mortality was assessed as a safety endpoint in both studies. Results: Serelaxin reduced 180-day mortality, with similar effects in the phase II and phase III studies (combined studies: N = 1,395; hazard ratio: 0.62; 95% confidence interval: 0.43 to 0.88; p = 0.0076). In RELAX-AHF, changes in markers of cardiac (high-sensitivity cardiac troponin T), renal (creatinine and cystatin-C), and hepatic (aspartate transaminase and alanine transaminase) damage and of decongestion (N-terminal pro-brain natriuretic peptide) at day 2 and worsening heart failure during admission were associated with 180-day mortality. Serelaxin administration improved these markers, consistent with the prevention of organ damage and faster decongestion. Conclusions: Early administration of serelaxin was associated with a reduction of 180-day mortality, and this occurred with fewer signs of organ damage and more rapid relief of congestion during the first days after admission.

KW - congestion

KW - heart failure

KW - organ protection

KW - RELAX-AHF

KW - serelaxin

UR - http://www.scopus.com/inward/record.url?scp=84871927704&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871927704&partnerID=8YFLogxK

U2 - 10.1016/j.jacc.2012.11.005

DO - 10.1016/j.jacc.2012.11.005

M3 - Article

VL - 61

SP - 196

EP - 206

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

SN - 0735-1097

IS - 2

ER -